Neurogene NGNE
NASDAQ NGNE
$28.39 -0.09 (-0.32%)
At close: Sep 29, 2026 · 4:00 PM EDT

Neurogene (NGNE) EBITDA Margin (2019 - 2024)

Updated

Neurogene (NGNE) posted EBITDA Margin of -8584.32% for FY2024.

Analysis

Neurogene (NGNE) EBITDA Margin (2019 - 2024) Analysis & Trends

  • Annual EBITDA Margin shows a five-year change of -8577.26 percentage points (FY2019 to FY2024).
  • The FY2024 figure stands as the highest annual EBITDA Margin since FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 Neurogene 642.28 Mn 642.28 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 -2,090.16%
Sep 30, 2019 -5.94%
API Access

Neurogene EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NGNE&period=max&api_key=YOUR_API_KEY